tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Catalyst Pharma Updates Guidelines for SCLC Treatment

Story Highlights
Catalyst Pharma Updates Guidelines for SCLC Treatment

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Catalyst Pharma ( (CPRX) ) just unveiled an announcement.

On August 6, 2025, Catalyst Pharmaceuticals announced that the National Comprehensive Cancer Network Clinical Practice Guidelines for Small Cell Lung Cancer now include Lambert Eaton myasthenic syndrome (LEMS), amifampridine, and tests for voltage-gated calcium channel antibodies. This update aims to improve diagnosis and treatment of LEMS in SCLC patients, potentially enhancing patient outcomes by raising clinical awareness and promoting comprehensive neurological evaluations.

The most recent analyst rating on (CPRX) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Catalyst Pharma stock, see the CPRX Stock Forecast page.

Spark’s Take on CPRX Stock

According to Spark, TipRanks’ AI Analyst, CPRX is a Outperform.

Catalyst Pharma’s strong financial performance and positive earnings call are the most significant factors driving the stock’s score. While technical indicators suggest caution, the company’s strategic initiatives and valuation support a favorable outlook.

To see Spark’s full report on CPRX stock, click here.

More about Catalyst Pharma

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients with rare and difficult-to-treat diseases. Headquartered in Coral Gables, Florida, Catalyst prioritizes patient care and accessibility through a comprehensive suite of support services. The company has been recognized as one of America’s Most Successful Mid-Cap Companies and one of North America’s Fastest-Growing Companies.

Average Trading Volume: 1,286,697

Technical Sentiment Signal: Buy

Current Market Cap: $2.71B

Find detailed analytics on CPRX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1